Genfit S.A. GNFTF

GNFTF Company Overview

Genfit S.A. is a French biopharmaceutical company focused on developing therapies and diagnostic solutions for severe chronic liver diseases and related metabolic disorders. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a concentration on conditions that have significant unmet medical needs, including acute-on-chronic liver failure (ACLF), cholangiocarcinoma, and other liver-related diseases. Genfit has historically been associated with research into nonalcoholic steatohepatitis (NASH), now more commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), though its strategic focus has broadened following changes in the competitive and clinical landscape.

The company’s principal revenue drivers have included research collaborations, licensing arrangements, milestone payments, and activities tied to its therapeutic development pipeline. Genfit has also developed diagnostic capabilities through its NIS4 technology platform intended to assist in identifying at-risk liver disease patients. Founded in 1999 and headquartered in Lille, France, Genfit evolved from a metabolic disease research company into a liver disease-focused biotechnology platform with international clinical development operations and partnerships across Europe and North America.